Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  BL22 immunotoxin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-4 of 4 for your search:
Start Over
Phase II Study of BL22 Immunotoxin in Patients With Cladribine-Resistant Hairy Cell Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-04-C-0014, NCI-6048, 6048, NCT00074048
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000066835, NCI-99-C-0014, NCI-T98-0063, NCT00021983
Phase I Study of BL22 Immunotoxin in Pediatric Patients With Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 6 months to 24 years
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-04-C-0079, NCI-5643, 5643, NCT00077493
Phase I Study of Recombinant BL22 Immunotoxin in Patients With CD22-Positive Refractory B-Cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Indolent Non-Hodgkin's Lymphoma
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-05-C-0171, NCI-P6620, NCI-5336, NCT00126646
Start Over